New hope for kids with rare liver cancer: smarter chemo aims to boost survival

NCT ID NCT07300449

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 18 times

Summary

This study is testing a new combination of chemotherapy drugs for children and teens with hepatoblastoma, a rare liver cancer. The goal is to improve survival, especially for high-risk patients who currently have only a 40% chance of living 3 years. The study will enroll 100 participants across 15 hospitals in China and also use a simple blood test to monitor the cancer more closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEPATOBLASTOMA HEPATOBLASTOMA